下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Analyzing Athenex (NASDAQ:ATNX) and ImmunoPrecise Antibodies (NASDAQ:IPA)
分析Athenex(纳斯达克:atnx)和免疫精准抗体(纳斯达克:ipa)

Defense World ·  {{timeTz}}

Athenex (NASDAQ:ATNX – Get Rating) and ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Athenex(纳斯达克:ATNX-GET评级)和免疫精抗体(纳斯达克:IPA-GET评级)都是小盘医疗公司,但哪只股票更好?我们将根据这两家公司的股息实力、分析师建议、机构所有权、风险、估值、收益和盈利能力对它们进行比较。

Earnings and Valuation

收益和估值

This table compares Athenex and ImmunoPrecise Antibodies' gross revenue, earnings per share and valuation.

下表比较了Athenex和免疫精选抗体公司的毛收入、每股收益和估值。

Get
到达
Athenex
Athenex
alerts:
警报:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athenex $120.18 million 1.11 -$199.77 million ($1.72) -0.64
ImmunoPrecise Antibodies $15.32 million 6.89 -$13.32 million ($0.68) -6.25
总收入 价格/销售额比 净收入 每股收益 市盈率
Athenex 1.2018亿美元 1.11 -1.997亿美元 ($1.72) -0.64
免疫精确化抗体 1,532万美元 6.89 -1332万美元 ($0.68) -6.25

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Athenex. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Athenex, indicating that it is currently the more affordable of the two stocks.

免疫精准抗体的收入低于Athenex,但收益高于Athenex。免疫精选抗体的市盈率低于Athenex,这表明它目前是两只股票中更负担得起的一只。

Risk & Volatility

风险与波动性

Athenex has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Athenex的贝塔系数为1.09,这意味着其股价的波动性比标准普尔500指数高出9%。相比之下,免疫精准抗体的贝塔系数为0.57,这意味着其股价的波动性比标准普尔500指数低43%。

Profitability

盈利能力

This table compares Athenex and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

此表比较了Athenex和免疫精选抗体公司的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
Athenex -160.39% -258.81% -43.21%
ImmunoPrecise Antibodies -86.21% -29.03% -24.23%
净利润率 股本回报率 资产回报率
Athenex -160.39% -258.81% -43.21%
免疫精确化抗体 -86.21% -29.03% -24.23%

Insider and Institutional Ownership

内部人与机构持股

40.9% of Athenex shares are held by institutional investors. Comparatively, 6.6% of ImmunoPrecise Antibodies shares are held by institutional investors. 12.0% of Athenex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

40.9%的Athenex股票由机构投资者持有。相比之下,免疫精抗体6.6%的股份由机构投资者持有。Athenex 12.0%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一家公司有望实现长期增长。

Analyst Ratings

分析师评级

This is a breakdown of recent ratings and recommmendations for Athenex and ImmunoPrecise Antibodies, as provided by MarketBeat.

这是由MarketBeat提供的对Athenex和免疫精制抗体的最近评级和推荐的细目。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athenex 0 1 1 0 2.50
ImmunoPrecise Antibodies 0 0 1 0 3.00
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
Athenex 0 1 1 0 2.50
免疫精确化抗体 0 0 1 0 3.00

Athenex presently has a consensus price target of $4.00, suggesting a potential upside of 263.64%. ImmunoPrecise Antibodies has a consensus price target of $12.00, suggesting a potential upside of 182.35%. Given Athenex's higher probable upside, research analysts plainly believe Athenex is more favorable than ImmunoPrecise Antibodies.

Athenex目前的共识目标价为4美元,暗示潜在上涨263.64%。免疫精制抗体的一致目标价为12.00美元,暗示潜在上涨182.35%。鉴于Athenex的上行可能性更高,研究分析师显然认为Athenex比免疫精制抗体更有利。

Summary

摘要

ImmunoPrecise Antibodies beats Athenex on 7 of the 13 factors compared between the two stocks.

免疫精准抗体在两只股票之间的13个因素中有7个击败了Athenex。

About Athenex

关于Athenex

(Get Rating)

(获取评级)

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Athenex,Inc.是一家生物制药公司,从事癌症治疗药物的发现、开发和商业化。它通过三个部分运作:肿瘤学创新平台、全球供应链平台和商业平台。该公司的Orascovery候选产品包括口服紫杉醇和Enequidar,这是一种口服剂型,正处于转移性乳腺癌的第三阶段试验,以及针对皮肤血管肉瘤、进展期胃癌和进展期实体恶性肿瘤的各种临床研究。它还提供由替巴尼布林软膏组成的Src Kinase候选产品,用于治疗光化性角化病、皮肤癌和牛皮癣。此外,该公司正在开发KUR-501,这是一种用于治疗复发难治性(R/R)高风险神经母细胞瘤的儿童的自体产品,处于I期临床试验;KUR-502,这是一种同种异体产品,处于治疗成人R/R CD19阳性恶性肿瘤的第一阶段临床试验,包括B细胞淋巴瘤、急性淋巴细胞白血病和慢性淋巴细胞白血病;以及KUR-503,这是一种处于晚期肝细胞癌临床前开发的同种异体产品,以及TCRT-ESO-A2,一种自体T细胞受体(TCR)T细胞疗法,处于实体肿瘤的第一阶段临床试验。此外,它正在开发双重吸收增强剂,以抑制胃肠道内的P-gp转运体和细胞色素P450 3A酶;并拥有一系列TCR,可识别多种肿瘤的P53、KRAS和EGFR基因的热点突变。该公司前身为Kinex PharmPharmticals LLC,并于2015年8月更名为Athenex,Inc.Athenex,Inc.成立于2003年,总部设在纽约州布法罗。

About ImmunoPrecise Antibodies

关于免疫精确化抗体

(Get Rating)

(获取评级)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

免疫精抗体有限公司及其子公司在美国、加拿大、欧洲和国际上从事抗体生产和相关服务。该公司提供一系列抗体、酶、酶活性分析、关节炎动物产品、蛋白质、去亚胺蛋白、有机生长因子和杂交瘤产品用于研究目的。其服务包括定制抗原建模、设计和制造;B细胞分类、筛选和测序;定制、免疫和天然噬菌体展示生产和筛选;转基因动物和多物种抗体发现;双特异性、三特异性、VHH和VNAR(鲨鱼)抗体制造;DNA克隆、蛋白质和抗体的下游加工;无标记生物传感器和抗体工程的抗体表征;瞬时和稳定的细胞系生成;抗体优化和人性化;多重杂交瘤的生产、高通量筛选和克隆挑选;以及冷冻保存。该公司与Pierre Fabre S.A公司签订了抗体发现方面的研究合作协议,并与Elektrofi公司签订了研究合作协议,以探索高浓度新冠肺炎抗体鸡尾酒配方多表位TATX-03。免疫精抗体有限公司成立于1983年,总部设在加拿大维多利亚。

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

接受Athenex日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Athenex和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部